Bill > HB766

This bill aims to ensure that health insurance plans provide coverage for orally administered anti-cancer medications on the same terms as intravenously administered or injected anti-cancer medications, a concept known as "parity." It clarifies that health coverage plans cannot impose stricter rules like higher copayments, deductibles, or more complex approval processes on oral cancer drugs compared to their injected counterparts, ensuring that patients and their doctors can choose the most effective treatment without financial barriers. The bill also mandates that any out-of-pocket costs paid by the patient for these oral medications count towards their annual deductible and maximum out-of-pocket spending, and prohibits insurance companies from using programs that reduce the value of manufacturer coupons or financial assistance towards these patient costs. This legislation applies to various types of health plans, including individual and group plans, high-deductible plans, and those offered through health benefit exchanges, while generally respecting self-funded employee benefit plans governed by federal law.

Business and Industry

https://www.legis.la.gov/legis/BillInfo.aspx?s=26rs&b=HB766&sbi=y